Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
2019 ◽
Vol 33
(12)
◽
pp. 2305-2312
◽
2015 ◽
Vol 22
(12)
◽
pp. 1131-1137
◽
Keyword(s):
2007 ◽
Vol 6
(1)
◽
pp. 51-51
2013 ◽
Vol 21
(4)
◽
pp. 342-347
◽
Keyword(s):
2021 ◽
pp. 247-259
Keyword(s):
2020 ◽
Vol 17
(19)
◽
pp. 7049